Umbilical Cord (At least 8 inches, approximately the width of a sheet of paper.)
Specimen Preparation
Drain and discard any blood. Rinse the exterior of the cord segment with normal saline or water. Pat the cord dry and transport at least 8 inches of umbilical cord in a routine urine collection cup or Security Kit for Meconium/Umbilical Drug Detection.
Unacceptable Conditions
Cords soaking in blood or other fluid. Formalin fixed. Tissue that is obviously decomposed.
Storage/Transport Temperature
Refrigerated.
Stability (from collection to initiation)
Ambient: 1 week; Refrigerated: 3 weeks; Frozen: 1 year
Cerner Orderable(s)
Cord Marijuana Metabolite Screen (SENDOUT)
Ordering Recommendations
Use to detect and document fetal exposure to THC during approximately the last trimester of a full-term pregnancy. For panel testing that includes THC metabolite, refer to Drug Detection Panel and THC Metabolite, Umbilical Cord Tissue, Qualitative (3006371).
This test does not distinguish between the delta-8 and delta-9 forms of THC or their metabolites.
Methodology
Qualitative Liquid Chromatography-Tandem Mass Spectrometry
Reported
Report available: 1-3 days
Synonyms
Drug Screen, Targeted, Serum or Plasma
Drugs of Abuse Panel, Meconium - Screen with Reflex to Confirmation/Quantitation
Reference Interval
Drugs/Drug Classes
Cutoff Concentrations (ng/g)
THC-COOH
0.2
Interpretive Data
Methodology: Qualitative Liquid Chromatography-Tandem Mass Spectrometry
This test is designed to detect and document exposure that occurred during approximately the last trimester of a full term pregnancy, to a common cannabis (marijuana) metabolite. Alternative testing is available to detect other drug exposures. The pattern and frequency of drug(s) used by the mother cannot be determined by this test. A negative result does not exclude the possibility that a mother used drugs during pregnancy. Detection of drugs in umbilical cord tissue depends on extent of maternal drug use, as well as drug stability, unique characteristics of drug deposition in umbilical cord tissue, and the performance of the analytical method. Drugs administered during labor and delivery may be detected. Detection of drugs in umbilical cord tissue does not insinuate impairment and may not affect outcomes for the infant. Interpretive questions should be directed to the laboratory.
This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.
CPT Codes
80349 (Alt code: G0480)
Performing Lab
ARUP Laboratores
Collection
Collect
Umbilical Cord (At least 8 inches, approximately the width of a sheet of paper.)
Specimen Preparation
Drain and discard any blood. Rinse the exterior of the cord segment with normal saline or water. Pat the cord dry and transport at least 8 inches of umbilical cord in a routine urine collection cup or Security Kit for Meconium/Umbilical Drug Detection.
Unacceptable Conditions
Cords soaking in blood or other fluid. Formalin fixed. Tissue that is obviously decomposed.
Storage/Transport Temperature
Refrigerated.
Stability (from collection to initiation)
Ambient: 1 week; Refrigerated: 3 weeks; Frozen: 1 year
Ordering
Cerner Orderable(s)
Cord Marijuana Metabolite Screen (SENDOUT)
Ordering Recommendations
Use to detect and document fetal exposure to THC during approximately the last trimester of a full-term pregnancy. For panel testing that includes THC metabolite, refer to Drug Detection Panel and THC Metabolite, Umbilical Cord Tissue, Qualitative (3006371).
This test does not distinguish between the delta-8 and delta-9 forms of THC or their metabolites.
Methodology
Qualitative Liquid Chromatography-Tandem Mass Spectrometry
Reported
Report available: 1-3 days
Synonyms
Drug Screen, Targeted, Serum or Plasma
Drugs of Abuse Panel, Meconium - Screen with Reflex to Confirmation/Quantitation
Result Interpretation
Reference Interval
Drugs/Drug Classes
Cutoff Concentrations (ng/g)
THC-COOH
0.2
Interpretive Data
Methodology: Qualitative Liquid Chromatography-Tandem Mass Spectrometry
This test is designed to detect and document exposure that occurred during approximately the last trimester of a full term pregnancy, to a common cannabis (marijuana) metabolite. Alternative testing is available to detect other drug exposures. The pattern and frequency of drug(s) used by the mother cannot be determined by this test. A negative result does not exclude the possibility that a mother used drugs during pregnancy. Detection of drugs in umbilical cord tissue depends on extent of maternal drug use, as well as drug stability, unique characteristics of drug deposition in umbilical cord tissue, and the performance of the analytical method. Drugs administered during labor and delivery may be detected. Detection of drugs in umbilical cord tissue does not insinuate impairment and may not affect outcomes for the infant. Interpretive questions should be directed to the laboratory.
This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.
